Immediate access to certified rodent and non-rodent model evaluations, natural compound potency determination, and cellular toxicity screening designed for Colombian investigators.
Full-scale in vivo pharmacological validation, acute/sub-chronic oral toxicity, and pharmacokinetics in SPF rodent colonies configured for Colombian regulatory submissions.
Explore Animal Study Protocols →
Disease-targeted rodent models including metabolic syndrome, anti-inflammatory pathways, and oncology xenografts adhering to international AAALAC standards.
View In Vivo Models →
Scientific screening and potency quantification across seasonal harvesting windows for Colombian Andean, Amazonian, and Pacific plant resources.
Inspect Botanical Potency Services →
Rapid high-throughput cell-based viability assays, receptor-binding profiling, and alternative non-animal toxicology screening for early-stage lead filtering.
Review In Vitro Screening →Strategic analysis of INVIMA requirements, biodiversity commercialization barriers, and the critical need for global animal study manufacturing partners.
The Republic of Colombia stands as Latin America’s third-largest pharmaceutical market and the world’s second most biodiverse nation per square kilometer. Over the past decade, Colombia’s National Food and Drug Surveillance Institute (INVIMA - Instituto Nacional de Vigilancia de Medicamentos y Alimentos) has undertaken profound regulatory modernizations, aligning national oversight with the Pan American Health Organization (PAHO) and international standards such as the International Council for Harmonisation (ICH) and the Organization for Economic Co-operation and Development (OECD). Furthermore, with Colombia’s adherence to the Andean Community of Nations (CAN - Comunidad Andina) Decisions 483 and 833, safety criteria for pharmaceuticals, phytotherapeutics, and veterinary biologicals require documented, non-negotiable preclinical empirical evidence.
Concurrently, Colombia enacted Law 1774 of 2016 (Animal Welfare & Protection) and Law 2047 of 2020, which strictly prohibits the testing of cosmetic products and their ingredients on animals within national borders. This landmark legislation, while elevating ethical standards, has fundamentally polarized Colombian industrial life sciences. Cosmetic companies are mandated to leverage advanced alternative in vitro assays, whereas human drug developers, medicinal plant researchers, and veterinary drug manufacturers face a drastic domestic vivarium bottleneck.
Academic centers such as Universidad Nacional de Colombia in Bogotá, Universidad de Antioquia in Medellín, and Universidad del Valle in Cali possess world-class pharmacological minds and an unparalleled botanical pipeline (ranging from Amazonian ethnobotanicals to *Cannabis sativa* cannabinoid isolates). However, domestic vivarium facilities are largely constrained to basic exploratory academic testing. Colombia experiences an acute domestic shortage of OECD-GLP certified bioterios (animal facilities) equipped for multi-generational reproductive toxicology, chronic carcinogenicity bioassays, telemetric hemodynamic recording, and full SEND-formatted data reporting. Consequently, innovative Colombian bio-ventures, phytopharmaceutical processors, and contract research sponsors face severe multi-year project stalls if they cannot secure reliable international animal study suppliers.
Colombia’s pharmaceutical manufacturing footprint is concentrated across three primary industrial poles, each presenting unique supply chain and testing demands:
Central hub of domestic and multinational drug formulators. Massive demand for INVIMA-compliant oral toxicology, bioequivalence PK profiles, and IND-enabling preclinical dossiers.
The tech and bio-innovation capital. High concentration of biotech startups, functional nutraceutical development, and advanced phytomedicine extraction platforms.
The heart of agrochemical, veterinary biological, and active pharmaceutical ingredient (API) synthesis. Driven by agro-industrial animal health trials and feed additive validations.
Preclinical documentation submitted to INVIMA’s Specialized Pharmacological Advisory Commission requires:
Overcoming geographical and budgetary barriers through high-precision vivarium automation, vast animal model availability, and radical turnaround compression.
Our centralized animal testing facilities in China operate strictly under AAALAC International accreditation and mutual OECD-GLP compliance. Every acute toxicity, sub-chronic rodent assay, and pharmacokinetic study generates audit-ready data recognized unconditionally by INVIMA, US FDA, and EMA regulators.
North American and European CROs impose prohibitively high fees for exploratory in vivo safety pharmacology, severely hampering Latin American R&D budgets. Chinese contract manufacturing delivers the same high-resolution histopathology and GLP toxicokinetics at less than half the financial overhead, maximizing project runway.
While local Colombian academic vivaria often require 9 to 14 months just to establish breeding pairs, review protocols, and procure bioanalytical standards, our scaled infrastructure initiates in-life dosing within 10 business days of protocol sign-off, delivering final audited dossiers within 8 to 12 weeks.
Access ready-to-dose cohorts of genetically modified rodents: Type 2 Diabetes (db/db, ob/ob), NASH/MASH dietary models, DSS-induced ulcerative colitis, syngeneic oncology models, and specialized vector-borne tropical infectious disease profiles mirroring Colombian public health challenges.
With 14+ years dedicated to modernizing 83 classic Traditional Chinese Medicine formulas and over 400 single-herb monographs, MedGence possesses specialized chromatographic fingerprinting (HPTLC, HPLC-MS) to quantify and test complex Colombian multi-component botanical mixtures in vivo.
Unlike standalone testing vivaria, our facility combines CRO testing with CDMO manufacturing. Validated animal study dosage preparations transition seamlessly into pilot-plant extraction, concentration, purification, and finished dosage formulation (tablets, softgels, oral liquids).
Structured testing regimes aligned with OECD Guidelines for Testing of Chemicals and ICH Safety Guidelines.
Procurement teams and Chief Scientific Officers (CSOs) in Colombia require rigorous methodological transparency when contracting offshore preclinical trials. To eliminate regulatory re-testing costs and guarantee instantaneous acceptance by INVIMA evaluators, our animal study pipeline follows standardized OECD and ICH test guidelines. The table below outlines our standard preclinical battery available for Colombian sponsors:
| Study Type | Test Guideline | Species / Strain | Primary Clinical Endpoints | Typical Timeline |
|---|---|---|---|---|
| Acute Oral Toxicity (UDP / Fixed Dose) | OECD 425 / OECD 420 | Sprague-Dawley Rats / CD-1 Mice | LD50 estimation, behavioral telemetry, gross necropsy, target organ acute vulnerability index. | 3 - 4 Weeks |
| Repeated Dose 28-Day Oral Toxicity | OECD 407 (GLP) | Wistar Rats (SPF Grade) | NOAEL determination, clinical hematology, clinical chemistry, comprehensive 40+ organ histopathology. | 8 - 10 Weeks |
| Sub-Chronic 90-Day Toxicity | OECD 408 (GLP) | Rats / Beagle Dogs | Cumulative systemic toxicity, metabolic impact, ophthalmology, immunotoxicity markers, organ weight ratios. | 16 - 18 Weeks |
| In Vivo Mammalian Micronucleus Test | OECD 474 | ICR Mice (Bone Marrow / Peripheral Blood) | Cytogenetic damage, chromosome aberration analysis via polychromatic erythrocytes (PCE/NCE ratio). | 4 - 6 Weeks |
| Safety Pharmacology Battery | ICH S7A / ICH S7B | Telemetry Guinea Pigs / Beagle Dogs | Cardiovascular evaluation (hERG, ECG, blood pressure), CNS (Irwin functional battery), respiratory plethysmography. | 6 - 8 Weeks |
| Pharmacokinetics & ADME | EMA/CHMP/EWP/192272 / FDA | Rats, Dogs, Cynomolgus Macaques | Cmax, Tmax, AUC(0-t), t1/2, bioanalytical LC-MS/MS biofluid quantitation, tissue distribution, protein binding. | 5 - 7 Weeks |
Each protocol includes real-time digital access to in-life observations, audited analytical chemistry validation reports (precision, accuracy, recovery, matrix effect), full color high-resolution microphotographs of histopathological lesions, and electronic Common Technical Document (eCTD) summary modules ready for immediate incorporation into Colombian registration dossiers.
Demonstrating tangible clinical and commercial impact across Colombian phytomedicine, agricultural health, and emerging biotherapeutic pipelines.
Client: Phytotherapeutic Manufacturer in Medellín, Colombia
The Challenge: A Colombian natural product laboratory developed a standardized ethanolic extract of Petiveria alliacea (Anamú) intended for immune modulation and adjuvant oncology care. Domestic academic laboratories were unable to provide GLP-certified 90-day sub-chronic toxicity data or pharmacodynamic cytokine response profiles in murine models required for an INVIMA "Medicamento Fitoterapéutico de Uso Tradicional / Científico" registration.
The Solution: MedGence executed standardized fingerprinting (HPLC) to establish active dibenzyl trisulfide concentrations, followed by OECD 408 sub-chronic toxicity assays in SPF Wistar rats and an in vivo syngeneic breast carcinoma model.
Outcome: The Colombian client secured an unconditioned INVIMA sanitary registry within 7 months, saving an estimated $140,000 USD compared to North American contract vivaria.
Client: Licensed Cannabis Producer in Rionegro (Antioquia)
The Challenge: Following the enactment of Colombia's Decree 811 of 2021 regarding industrial cannabis use, the client required detailed animal bioavailability and pharmacokinetic (PK) comparative curves between a novel water-soluble nano-emulsion CBD formulation and standard MCT-oil oral drops to validate European and Latin American distribution dossiers.
The Solution: MedGence conducted single-dose cross-over PK studies in Sprague-Dawley rats via jugular vein catheterization, analyzing CBD, 7-OH-CBD, and THC trace metabolites at 12 discrete time points via LC-MS/MS.
Outcome: The nano-emulsion demonstrated a 340% increase in AUC(0-24h) and a 50% faster Tmax, providing conclusive marketing and scientific evidence that closed multi-million-dollar supply agreements in Brazil and Germany.
Client: Agro-industrial Corporation in Valle del Cauca
The Challenge: Colombia’s beef and poultry sectors face stringent ICA (Instituto Colombiano Agropecuario) regulations regarding antibiotic-free growth promoters. The client synthesized a botanical alkaloid blend to mitigate enteric coccidiosis and improve weight gain in broiler poultry, requiring pilot target-animal tolerance and safety studies.
The Solution: We performed targeted safety index margin-of-safety evaluations in rodents alongside preliminary intestinal barrier histology, followed by pilot in vivo efficacy screening in broiler chickens under controlled challenge conditions.
Outcome: ICA approval was granted with zero requests for additional safety clarification, enabling rapid commercial scaling across 45 livestock cooperatives in Colombia.
Quantified excellence developed through 14+ years of industrial pharmacological execution.
Overcoming cold-chain biological transport, customs clearance, and data-protection protocols seamlessly.
Exporting crude plant extracts, novel synthetic APIs, or chemical entities from Colombia requires meticulous coordination between the Ministry of Environment (MinAmbiente - genetic resource access permits where applicable) and DIAN (Dirección de Impuestos y Aduanas Nacionales).
MedGence provides Colombian sponsors with turnkey import permits into China via the General Administration of Customs of the People's Republic of China (GACC). We handle temperature-monitored international air cargo (dry ice / -20°C / -80°C continuous loggers) from El Dorado International Airport (Bogotá) or José María Córdova (Medellín) directly to our Changsha research hub, ensuring 0% compound degradation prior to test formulation homogenization.
Transcontinental contract research demands complete methodological oversight. Colombian research directors are equipped with dedicated encrypted client portal access:
Explore our 8 specialized contract development, analytical method validation, and clinical evaluation service packages.
GLP-compliant acute, sub-acute, and sub-chronic toxicity assays in validated rodent models with full macroscopic and microscopic organ histopathology.
Study Specifications →
Specialized preclinical target validation, diabetic complications, anti-inflammatory arthritis models, and custom in vivo pharmacodynamic screening.
Review Model Library →
Comparative bio-potency mapping of active phytochemical fractions evaluating diverse Colombian microclimates, harvest altimetry, and processing variations.
Evaluation Methodology →
Multi-cell line cytotoxicity screening, IC50 determination, MTT/LDH assays, and mechanistic molecular signaling assays adhering to ISO/OECD standards.
Explore In Vitro Assays →
Development and ICH Q2(R1) validation of HPLC, HPTLC, and GC chromatographic fingerprinting techniques for complex Colombian plant matrices.
Analytical Capabilities →
Translating preclinical successes into GCP-compliant human clinical trials: safety escalation, bioequivalence trials, and multi-center efficacy programs.
Clinical Trial Pipeline →
Target-oriented bio-guided fractionation, LC-MS/MS peak dereplication, and chemical library screening for Colombian biodiversity bioprospecting programs.
Bioprospecting Services →
Direct translation from in vivo validated animal dosing batches into commercial scale-up: extraction, spray-drying, and tablet/capsule/liquid packaging.
Request Turnkey CDMO →Clear answers addressing regulatory acceptance, bioethics, logistics, and data ownership.
Yes, absolutely. INVIMA’s Specialized Advisory Commissions (Comisión Revisora de Medicamentos y Productos Biológicos) evaluate international preclinical toxicology and pharmacology dossiers based on adherence to the OECD Principles of Good Laboratory Practice (GLP) and recognized international standards (ICH, WHO, ISO). Because MedGence facilities operate under strict OECD-GLP compliance and AAALAC accreditation, our study reports include all necessary quality assurance (QA) statements, raw data archives, microphotographs, and bioanalytical validation curves required by Colombian technical reviewers without necessitating local re-testing.
Colombia’s Law 2047 strictly prohibits in vivo animal testing within Colombia and forbids importing cosmetic products whose final formulations or ingredients underwent animal testing post-enactment. However, this ban specifically governs cosmetic claims. If your compound is intended as a pharmaceutical, fitoterapéutico (phytotherapeutic drug), medical device, or veterinary active ingredient, animal studies remain legally mandatory under INVIMA and ICA guidelines. For cosmetic clients, MedGence provides comprehensive alternative in vitro testing suites (reconstructed human epidermis models, EpiDerm, 3T3 NRU phototoxicity, and bovine corneal opacity BCOP assays).
We provide our Colombian partners with an end-to-end sample intake protocol. For non-restricted processed botanical extracts or chemical compounds, we issue standard Chinese Import Quarantine Notifications and supply temperature-controlled packaging guidelines. Shipments are flown directly via certified biopharma couriers (e.g., World Courier or DHL Medical Express) from Bogotá (BOG) to our central laboratory. We monitor temperature with continuous NIST-calibrated data loggers to guarantee compound integrity upon arrival.
Yes. In addition to standard regulatory toxicology (OECD 420, 423, 425, 407, 408), our in vivo pharmacology team designs tailored efficacy models. These include diet-induced obesity (DIO), streptozotocin (STZ)-induced diabetes, carbon tetrachloride (CCl4) liver fibrosis, DSS-induced inflammatory bowel disease, neurodegenerative models (Parkinson's/Alzheimer's), and syngeneic subcutaneous oncology xenografts.
We operate exclusively under an entrusted Contract Research Organization model. All intellectual property, study outcomes, chemical synthesis pathways, and analytical discoveries generated during the contract belong 100% to the Colombian sponsor. Before receiving any sample or confidential brief, we execute a legally binding Non-Disclosure Agreement (NDA) governed by international commercial law. Furthermore, our internal scientists operate in segregated project cells to prevent cross-contamination of proprietary data.
Evaluating multi-component botanical preparations requires specialized phytochemical and chromatographic capacity that standard chemical vivaria lack. With over 14 years modernizing 83 classic Traditional Chinese Medicine formulas, our analytical laboratory utilizes High-Performance Thin-Layer Chromatography (HPTLC) and Ultra-High Performance Liquid Chromatography coupled with High-Resolution Mass Spectrometry (UHPLC-HRMS) to establish chemical fingerprints and identify active marker compounds before, during, and after in vivo dosing.
Standard acute toxicity protocols (OECD 425) are typically completed with audited draft reports within 3 to 4 weeks from sample arrival. Sub-chronic 28-day studies (OECD 407) require approximately 8 to 10 weeks, and 90-day repeated dose oral toxicity studies (OECD 408) require 16 to 18 weeks. Exploratory in vitro screening data can be delivered in as little as 10 business days.
Yes. Colombian clients are warmly welcomed to visit our state-of-the-art facility in Changsha, China, in person. Alternatively, for sponsors unable to travel internationally, we host secure live video audits. Our QA officers guide you through vivarium corridors, barrier systems, individual ventilation racks, surgical preparation rooms, and analytical instrument suites in real time.
Once your active ingredient or formula demonstrates safety and efficacy in animal trials, our pilot plant and industrial CDMO facilities can scale your product into concentrated liquids, atomized extract powders, viscous pastes, or volatile essential oils. For finished retail or clinical trial materials, we formulate two-piece hard capsules, softgels, micro-tablets, effervescent powders, oral solutions, and functional sachets.
On average, an identical OECD-GLP compliant 28-day repeated oral toxicity study conducted with comprehensive histopathology costs between $65,000 to $95,000 USD at Tier-1 North American or Western European CROs. MedGence delivers equivalent scientific rigor, full QA documentation, and AAALAC animal care standards at approximately $28,000 to $42,000 USD—generating a 50% to 60% operational savings that directly benefits Colombian pharmaceutical enterprise viability.
Connect directly with our senior toxicologists and bioanalytical directors. Submit your study brief for immediate protocol drafting, OECD-GLP scoping, and transparent pricing tailored to INVIMA regulatory timelines.
